RemovedRisk Factors
The principal assumptions relating to our determination of the TAM includes determining the total number of physicians in the geographic market reduced by hospital employed physicians and other Privia Physicians in the market that are unlikely to change their
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
participants, health system or hospital partners, patients, or payers, which could harm our business, results of operations and financial condition.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
The risks of geographic concentration could decrease as we expand the operations of the Company and its Medical Groups to other regions of the United States, but expansion is resource-intensive and we may encounter significant barriers to entry in new markets.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
We anticipate that further geographic expansion may require us to make a substantial investment of management time, capital and/or other resources. There can be no assurance that we will be able to continue to successfully expand our operations in any new geographic markets.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
Information technology is a critical component of the day-to-day business operations of the Company and its Medical Groups. Our business is highly dependent on maintaining effective information systems, in part because VBC arrangements involve extensive data
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
Monitoring unauthorized use of our intellectual property is difficult and costly. From time to time, we seek to analyze our competitors’ services, and may in the future seek to enforce our rights against potential infringers. However, the steps we have taken to protect our intellectual property rights may not be adequate to prevent infringement, misappropriation or other violations of our intellectual property. We may not be able to detect unauthorized use of, or take appropriate steps to enforce, our intellectual property rights. Any inability to meaningfully protect our intellectual property rights could result in harm to our ability to compete and reduce demand for our technology. Moreover, our failure to develop and properly manage new intellectual property could adversely affect our market positions and business opportunities. Also, some of our services rely on technologies and software developed by or licensed from third parties, and we may not be able to maintain our relationships with such third parties or enter into similar relationships in the future on reasonable terms or at all.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
The AI field is complex and rapidly evolving, and we face significant competition from other companies in our industry. Our efforts in developing and deploying AI may not succeed and our competitors may be able to deploy the technology faster. We may further be
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
physicians is limited by the federal Anti-Kickback Statute, the Stark Law, and other applicable laws and regulations intended to prevent fraud and abuse.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
Most members of our management team have limited experience managing a publicly traded company, interacting with public company investors and complying with the increasingly complex laws pertaining to public companies. Our management team may not successfully or efficiently manage us as a public company that is subject to significant regulatory oversight and reporting obligations under the federal securities laws and the continuous scrutiny of securities analysts and investors. These obligations and constituents require significant attention from our senior management and could divert their attention away from the day-to-day management of our business, which could adversely affect our business, results of operations and financial condition.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
During periods of high unemployment and inflation, governmental entities often experience budget deficits as a result of increased costs and lower than expected tax collections. Budget deficits at the federal level and within some state and local government entities have had a negative impact on spending for many health and human services programs, including Medicare, Medicaid and similar programs, which represent significant payer sources for our Medical Groups. We anticipate that budget deficits, the growing magnitude of Medicare and Medicaid expenditures and the aging of the U.S. population, among other factors, will continue to place pressure on government healthcare programs. Other risks we face during periods of economic weakness and high unemployment
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RewordedRisk Factors
Compliance with the evolving landscape of privacy, data protection and information security laws and regulations could be time-consuming and expensive and require changes to our current processes and practices, and any failure by us or our Medical Groups to comply with these and any other comprehensive privacy laws passed at the state or federal level may result in regulatory enforcement action, civil litigation and reputational harm.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
Further, we, Such disruptions could hinder our Medical Groups and Privia Providers could be unable ability to implement clinical initiatives to manage healthcare conditions of patients and appropriately document patient risk profiles, and any such public health crisis could impact adversely impacting our ability to accurately project medical cost trends. trends, increase patients’ clinical disease burdens or reduce preventive care.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, advances in AI technology may exacerbate these risks, including the risk that existing intellectual property laws may not adequately protect against advances in AI technology, which may also give giving rise to a proliferation of infringement which we may not be able to address effectively, and effectively; the risk that the use of generative AI tools could result in us inadvertently disclosing trade secrets or other confidential information. information; and the risk that the use of generative AI in the creation of our source code may not be protectable under existing intellectual property laws.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
Costs of medical supplies supplies, drugs and drugs other goods may continue to increase due to market pressure from pharmaceutical companies and vendors, new product releases, product shortages and other factors including import/export restrictions, such as new, expanded or retaliatory tariffs, sanctions, quotas or trade barriers (including recent recently-imposed U.S. tariffs imposed or threatened to be imposed on China, Canada and Mexico and other countries and any retaliatory reciprocal tariffs or similar actions taken by such target countries).
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
The Company and its Medical Groups are also subject to various federal and state antitrust laws that, for example, restrict exclusive contracting relationships with healthcare providers, restrict sharing of cost and pricing data, prohibit competitors from taking collective action to set commercial payer reimbursement rates, and establish integration requirements (financial risk or clinical integration) for joint ventures or healthcare networks to jointly contract with payers.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
Changes in the law’s implementation, subsequent legislation and regulations, state initiatives and other factors, including potential changes to or repeal of the Affordable Care Act ACA such as a result of changes those contained in the political landscape, One Big Beautiful Bill Act of 2025 (“OBBBA”), have affected, and may continue to affect affect, the number of individuals that elect to obtain public or private health insurance or the scope of such coverage.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
If a health system partner that is the majority owner of a Non-Owned Medical Group terminates our partnership or affiliation, we may not be able to identify an alternative partner to implement the operating model or restructure in a way to retain a sufficient number of Privia Physicians, which may restrict our ability to continue operations in that market.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
Expectations regarding voluntary ESG initiatives and disclosures may result in increased costs (including but not limited to increased costs related to compliance, stakeholder engagement, contracting and insurance), enhanced compliance or disclosure obligations, or other adverse impacts to our business, financial condition, or results of operations.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
The VBC revenues of the Company and Company, its Medical Groups Groups, and ACOs are subject to risks including managing established established, and any changes to, targets relative to utilization by patients, unit cost and the mix of healthcare services, services; annual fluctuations in payment terms for certain VBC arrangements, such as Medicare Advantage payment rates, rates and care coordination fees; changes in patient attribution, attribution and attribution methodologies; and changes in plan design and other terms by payers.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
If we inappropriately use or incorporate open source software subject to certain types of open source licenses that challenge the proprietary nature of our technology-enabled platform and service, the Privia Technology Solution, we may be required to re-engineer our platform, the Privia Technology Solution, discontinue the commercialization of our platform the Privia Technology Solution or take other remedial actions, any of which could adversely impact our business, financial condition condition, cash flows, and results of operations.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our operating model and growth strategy rely on aggregating a sufficient number of Privia Physicians in each Medical Group, as the number of Privia Physicians in a particular market impacts our attributed lives for VBC purposes, our costs and our Medical Groups’ costs, and our revenues from management services.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our operating model and growth strategy rely on aggregating a sufficient number of Privia Physicians in each Medical Group, as the number of Privia Physicians in a particular market impacts our attributed lives for VBC purposes, our costs and our Medical Groups’ costs, and our revenues from management services.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Some Many private third-party payers are also transitioning toward APMs or implementing other VBC strategies.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Reductions in the quality of services furnished by our Medical Groups, Privia Providers or ACO participants could have a material materially adverse effect on our business, results of operations, financial condition and cash flows.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
In addition, any factor that diminishes our reputation or that of our management, including failing to meet the expectations of our Medical Groups, Privia Physicians, ACO participants, health system or hospital partners, patients, or payers, or any adverse publicity or litigation involving or surrounding us, one any of our Medical Groups, Privia Providers or our management, could make it substantially more difficult for us to attract new Privia Physicians, New Medical Group, or retain existing Privia Providers and Medical Groups.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Current and future initiatives related to health care technology (including AI and other predictive algorithms), data sharing and interoperability may require changes to the operations of the Company and its Medical Groups, impose new and complex regulatory and compliance obligations and require potentially significant investments in infrastructure.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
In April 2025, we announced a partnership with Integrated Medical Services, a multi-specialty practice, to launch Privia Medical Group Arizona (“PMG AZ”). Privia acquired a majority ownership in PMG AZ.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
In December 2025, we acquired Evolent Health, Inc.’s accountable care business, adding over 120,000 attributed lives through the MSSP, as well as various commercial and Medicare Advantage programs.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
For the Years Ended December 31, 2025 2024 2023 (in thousands) Consolidated Statements of Cash Flows Data: Net cash provided by operating activities $ 163,404 $ 109,282 $ 80,785 Net cash used in investing activities (181,570) (11,978) (42,971) Net cash provided by financing activities 6,702 4,334 3,705 Net (decrease) increase in cash and cash equivalents $ (11,464) $ 101,638 $ 41,519
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
Accounting for business combinations requires us to allocate the fair value of purchase considerations to the tangible assets acquired, liabilities assumed, and intangible assets acquired based on their estimated fair values, which were determined primarily using the income method. The excess of the fair value of purchase consideration over the fair values of these identified assets and liabilities is recorded as goodwill. Such valuations require us to make significant estimates and assumptions, especially at the acquisition date with respect to intangible assets. Significant estimates in valuing certain intangible assets include, but are not limited to, revenue growth and attrition rates, medical claims expense, cost of care expenses, operating expenses, discount rate, contract terms and useful life from acquired assets.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
AddedMD&A
Our estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Allocation of purchase consideration to identifiable assets and liabilities affects our amortization expense, as acquired finite-lived intangible assets are amortized over the useful life, whereas any indefinite lived intangible assets, including goodwill, are not amortized. During the measurement period, which is not to exceed one year from the acquisition date, we may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period, any subsequent adjustments are recorded to earnings. For additional details, refer to Note 3. “Business Combinations.”
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RemovedMD&A
Based upon our experience to date, we believe Privia can succeed in all reimbursement environments and payment models. The data we collected from older provider cohorts consistently suggest that we improve their performance in both FFS and VBC metrics over
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
As of December 31, 2024, the total number of Privia-owned ACOs is nine, serving beneficiaries across the District of Columbia and eleven states, including California, Connecticut, Florida, Georgia, Maryland, Montana, North Carolina, Tennessee, Texas, Virginia, and Washington state.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RewordedMD&A
FFS–patient care revenue and FFS-administrative services, which increased $169.5 $214.1 million and $12.3 $11.6 million, primarily attributable to the addition of new providers and an increase in visit volume; an increase in PMPM capitated revenue of $13.5 $95.5 million primarily due to increased an increase in Attributed Lives; Lives related to capitated arrangements, improved contract terms and an increase in estimated per capita revenue; shared savings revenue, which increased $9.1 $55.6 million primarily due to more Attributed Lives in Medicare programs as well as continued strong estimated performance in our value based care programs in the aggregate. aggregate; and an increase in PMPM revenue of $9.1 million primarily due to increased Attributed Lives.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Adjusted EBITDA Margin was 22.4% 27.2%, 22.4%, and 20.1% for the year years ended December 31, 2024 an increase from 20.1% for the same period 2025, 2024, and 2023, respectively, in 2023 each case due to organic growth of our medical practice business and an increase from 19.9% in 2022, due to organic inorganic growth of our medical practice business, new market entry growth in Attributed Lives and a focus on managing the investment in new expenses.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Adjusted EBITDA increased 38.8% for the year ended December 31, 2025, as compared to the same period in 2024, and 25.2% for the year ended December 31, 2024, when as compared to the same period in 2023 2023, in each case due to organic and inorganic growth of our medical practice business and growth in Attributed Lives and increased 18.7% between 2022 and 2023 due to organic growth of our medical practice business, new market entry and a focus on managing the investment in new expenses.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
The increase was driven by the increase of $11.2 $6.5 million in stock-based compensation expense, which is primarily related to an additional quarter of expense due to timing of the 2023 equity awards being granted during the second quarter of 2023 compared to 2024 equity awards being granted during the first quarter of 2024, an increase in salaries and benefits of $1.7 $3.6 million and an increase in professional services of $1.1 $2.4 million related to additional consulting services.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
The increase was driven by an increase in salaries and benefits of $11.2 million related to continued growth, $11.4 million, an increase in stock-based compensation expense of $6.8 $6.6 million, primarily related to an increase in stock-based awards granted in 2024 2025 compared to 2023, 2024, and an increase of $6.1 million in platform costs of $6.5 million professional services primarily due to an increase continued growth in Implemented Providers and an increase in consulting costs of $3.3 million due to continued growth and market expansion.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
The Company is paid the financial incentives Incentive payments are earned when, for a given twelve-month measurement period, its performance on quality of care and utilization the Company meets or exceeds the quality and utilization standards set established by the payers as outlined in the contracts payer and when achieves savings are achieved for on medical costs associated with for the population of attributed members.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
As a percentage of revenue, Care Margin was 23.3% for the year ended December 31, in 2024 an increase from 21.7% for the same period in 2023 2023, due to renegotiated certain at-risk capitation agreements for a more favorable contract structure which is reflected on a net basis under shared savings starting in 2024 and a decrease from 22.5% in 2022, due to the addition of the at-risk capitation arrangements during 2022 and 2023 resulting in higher revenues. 2024.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
For the Years Ended December 31, (unaudited and amounts in thousands) 2025 2024 2023 2022 Net income (loss) attributable to Privia Health Group, Inc. $ 22,919 $ 14,385 $ 23,079 $ (8,585) Net income (loss) attributable to non-controlling interests 6,807 2,659 (2,051) (3,479) Provision for (benefit from) income taxes 14,212 10,826 7,993 (6,516) Interest income, net (9,703) (10,888) (8,372) (542) Depreciation and amortization 9,907 7,268 6,533 4,571 Stock-based compensation 71,068 56,680 37,098 67,359 Other expenses(1) 10,339 9,525 7,948 8,044 Adjusted EBITDA $ 125,549 $ 90,455 $ 72,228 $ 60,852 (1) Other expenses include employer taxes on equity vesting/exercises, legal, vesting and exercises, severance and retention costs and certain other non-recurring costs.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Care Margin increased 12.4% 14.4% for the year ended December 31, 2024 2025 when compared to the same period in 2023 2024 and increased 17.5% between 2023 and 2022, 12.4% as of the year ended December 31, 2024, as compared to the same period in 2023, in each case due to organic growth of our medical practice business.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
Platform Contribution increased 12.8% 20.0% for the year ended December 31, 2024 2025 when compared to the same period in 2023 2024 and increased 16.8% 12.8% between 2023 2024 and 2022, 2023, in each case due to organic and inorganic growth of our medical practice business and new market entries. a change in estimate related to our Shared Savings accrual.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
The To determine the amount of shared savings payments, payers analyze evaluate the activities Company’s performance during the measurement period using the agreed upon agreed-upon benchmarks, metrics and performance criteria to determine the appropriate payments to the Company. criteria.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
RewordedMD&A
In addition to increasing our provider base and contracted rates over time, we also seek to increase patient volume by demonstrating the ability to provide a better patient experience that leads to higher retention rates and drives referrals to preferred, high quality and value-based providers.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
Quiet changesMD&A
Our ability to increase our provider base will enable enables us to deliver financial growth as our providers generate both our FFS and VBC revenue.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
Quiet changesMD&A
Our ability to add new patients to our provider base in existing and new markets will also enable enables us to deliver revenue growth in both our FFS and VBC contracts.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new
Quiet changesMD&A
If we are unable to raise additional capital when desired, or if we cannot expand our operations or otherwise capitalize on our business opportunities because we lack sufficient capital, our business, results of operations, and financial condition would may be adversely affected.
Read it in 10-K Feb 27, 2026 at sec.govopen_in_new